The DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
IFN-γ: A cytokine at the right time, is in the right place
Open accessAbstract
Interferon gamma has long been studied as a critical mediator of tumor immunity. In recent years, the complexity of cellular interactions that take place in the tumor microenvironment has become better appreciated in the context of immunotherapy. While checkpoint inhibitors have dramatically improved remission rates in cancer treatment, IFN-γ and related effectors continue to be identified as strong predictors of treatment success. In this review, we provide an overview of the multiple immunosuppressive barriers that IFN-γ has to overcome to eliminate tumors, and potential avenues for modulating the immune response in favor of tumor rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Interleukin-10-deficient mice develop chronic enterocolitis
Kühn, R., Löhler, J., Rennick, D., Rajewsky, K., & Müller, W. (1993) · Cell · doi:10.1016/0092-8674(93)80068-p · Cited by 4,274
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046 · cited 1×
“Additionally, their development is also favored by exposure to lactic acid and contact with apoptotic cells or damage-associated molecular patterns (DAMPs) which are distributed through tumor tissue [155,156].”
BackgroundTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Fiorentino, D. F., Bond, M. W., & Mosmann, T. R. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.6.2081 · Cited by 2,733
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,094
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.011 · Cited by 2,039
de Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M. G., te Velde, A., Figdor, C., Johnson, K., Kastelein, R., Yssel, H., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.4.915 · Cited by 1,930
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R., & Ahmed, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4911-4927.2003 · Cited by 1,610
Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset
Cooper, M. A., Fehniger, T. A., Turner, S. C., Chen, K. S., Ghaheri, B. A., Ghayur, T., Carson, W. E., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.10.3146 · Cited by 1,449
D'Andrea, A., Aste-Amezaga, M., Valiante, N. M., Ma, X., Kubin, M., & Trinchieri, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.1041 · Cited by 1,385
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · cited 1×
“Indeed, FDAapproved monoclonal antibodies directed against PD-1, PD-L1 or CTLA-4 have proven effective at interfering with the immunosuppressive effects that are exerted by tumor tissues on cytotoxic T cells [167].”
BackgroundLoss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300 · cited 1×
“In tumor cells, IFN-γ also induces the expression of MHC-I and STAT1 associated cyclin dependent kinase resulting in apoptosis of tumor cells and immune recognition [47,71].”
BackgroundIL-12 family cytokines: immunological playmakers
Vignali, D. A. A., & Kuchroo, V. K. (2012) · Nature Immunology · doi:10.1038/ni.2366 · Cited by 1,297
CTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216 · cited 2×
“This activity is thought to occur primarily through a loss of IFN-γ signaling sensitivity, reduced antigen presentation [75] and induction of indolamine 2, 3-dioxygenase (IDO) [76] and checkpoint inhibitors [77].”
BackgroundAltered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,174
Genin, M., Clement, F., Fattaccioli, A., Raes, M., & Michiels, C. (2015) · BMC Cancer · doi:10.1186/s12885-015-1546-9 · Cited by 1,090 · cited 3×
“Du C, Sriram S, Mechanism of inhibition of LPS-induced IL-12p40 production by IL-10 and TGF-beta in ANA-1 cells, J. Leukoc.”
BackgroundInfluentialT cell apoptosis by tryptophan catabolism
Fallarino, F., Grohmann, U., Vacca, C., Bianchi, R., Orabona, C., Spreca, A., Fioretti, M. C., & Puccetti, P. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401073 · Cited by 1,022
Meurs, E., Chong, K., Galabru, J., Thomas, N. S. B., Kerr, I. M., Williams, B. R. G., & Hovanessian, A. G. (1990) · Cell · doi:10.1016/0092-8674(90)90374-n · Cited by 1,017
MECHANISMS OF MHC CLASS I–RESTRICTED ANTIGEN PROCESSING
Pamer, E., & Cresswell, P. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.323 · Cited by 1,008
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008
Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
ROSENBERG, S. A., LOTZE, M. T., YANG, J. C., AEBERSOLD, P. M., LINEHAN, W. M., SEIPP, C. A., & WHITE, D. E. (1989) · Annals of Surgery · doi:10.1097/00000658-198910000-00008 · Cited by 1,002
Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.024 · Cited by 966
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Cassetta, L., Fragkogianni, S., Sims, A. H., Swierczak, A., Forrester, L. M., Zhang, H., Soong, D. Y. H., Cotechini, T., Anur, P., Lin, E. Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.009 · Cited by 920
The roles of IFNγ in protection against tumor development and cancer immunoediting
Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00038-7 · Cited by 899
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Cole, K. E., Strick, C. A., Paradis, T. J., Ogborne, K. T., Loetscher, M., Gladue, R. P., Lin, W., Boyd, J. G., Moser, B., Wood, D. E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2009 · Cited by 870
Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820
Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway
Ulloa, L., Doody, J., & Massagué, J. (1999) · Nature · doi:10.1038/17826 · Cited by 812
Assembly, Transport, and Function of MHC Class II Molecules
Cresswell, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.immunol.12.1.259 · Cited by 807
Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787
Gazzinelli, R. T., Wysocka, M., Hayashi, S., Denkers, E. Y., Hieny, S., Caspar, P., Trinchieri, G., & Sher, A. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.6.2533 · Cited by 729
Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin
Wheelock, E. F. (1965) · Science · doi:10.1126/science.149.3681.310 · Cited by 725
Chin, Y. E., Kitagawa, M., Su, W.-C. S., You, Z.-H., Iwamoto, Y., & Fu, X.-Y. (1996) · Science · doi:10.1126/science.272.5262.719 · Cited by 696
A functional interleukin 12 receptor complex is composed of two β-type cytokine receptor subunits
Presky, D. H., Yang, H., Minetti, L. J., Chua, A. O., Nabavi, N., Wu, C.-Y., Gately, M. K., & Gubler, U. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14002 · Cited by 689
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Tolerance and exhaustion: defining mechanisms of T cell dysfunction
Schietinger, A., & Greenberg, P. D. (2014) · Trends in Immunology · doi:10.1016/j.it.2013.10.001 · Cited by 673
Stern, A. S., Podlaski, F. J., Hulmes, J. D., Pan, Y. C., Quinn, P. M., Wolitzky, A. G., Familletti, P. C., Stremlo, D. L., Truitt, T., & Chizzonite, R. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6808 · Cited by 670
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., De Palma, A., Mauri, P., Monegal, A., Rescigno, M., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101956 · Cited by 650
Bv8 regulates myeloid-cell-dependent tumour angiogenesis
Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X.-H., Yao, J., Blanchard, D., Bais, C., Peale, F. V., van Bruggen, N., et al. (2007) · Nature · doi:10.1038/nature06348 · Cited by 644
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W., Moskovitz, J. M., Kolls, J. K., Sander, C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.005 · Cited by 627
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma
Rodriguez, P. C., Hernandez, C. P., Quiceno, D., Dubinett, S. M., Zabaleta, J., Ochoa, J. B., Gilbert, J., & Ochoa, A. C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050715 · Cited by 609
de Waal Malefyt, R., Yssel, H., & de Vries, J. E. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.11.4754 · Cited by 603
Deiss, L. P., Feinstein, E., Berissi, H., Cohen, O., & Kimchi, A. (1995) · Genes & Development · doi:10.1101/gad.9.1.15 · Cited by 592
Chmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
New insights into IL-12-mediated tumor suppression
Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., vom Berg, J., Kulig, P., & Becher, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.134 · Cited by 558
Activation of the STAT Signaling Pathway Can Cause Expression of Caspase 1 and Apoptosis
Chin, Y. E., Kitagawa, M., Kuida, K., Flavell, R. A., & Fu, X.-Y. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5328 · Cited by 521
Immune suppressive mechanisms in the tumor microenvironment
Munn, D. H., & Bronte, V. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.10.009 · Cited by 519
Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets.
Kasahara, T., Hooks, J. J., Dougherty, S. F., & Oppenheim, J. J. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.4.1784 · Cited by 479
Gökbuget, N., Stanze, D., Beck, J., Diedrich, H., Horst, H.-A., Hüttmann, A., Kobbe, G., Kreuzer, K.-A., Leimer, L., Reichle, A., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399287 · Cited by 472
An Interleukin (IL)-10/IL-12 Immunoregulatory Circuit Controls Susceptibility to Autoimmune Disease
Segal, B. M., Dwyer, B. K., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.537 · Cited by 469
Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 465
γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity
Gao, Y., Yang, W., Pan, M., Scully, E., Girardi, M., Augenlicht, L. H., Craft, J., & Yin, Z. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030584 · Cited by 453
Topalian, S. L., Solomon, D., Avis, F. P., Chang, A. E., Freerksen, D. L., Linehan, W. M., Lotze, M. T., Robertson, C. N., Seipp, C. A., & Simon, P. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.5.839 · Cited by 440
Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells
Hanson, E. M., Clements, V. K., Sinha, P., Ilkovitch, D., & Ostrand-Rosenberg, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804253 · Cited by 427
Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., & Darnell, J. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7673 · Cited by 422
Orange, J. S., & Biron, C. A. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.12.4746 · Cited by 418
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., Blaisdell, S., Basham, B., Dai, J., Grein, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.003 · Cited by 418
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 418
Feng, J., Yang, H., Zhang, Y., Wei, H., Zhu, Z., Zhu, B., Yang, M., Cao, W., Wang, L., & Wu, Z. (2017) · Oncogene · doi:10.1038/onc.2017.188 · Cited by 415
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Yeku, O. O., Purdon, T. J., Koneru, M., Spriggs, D., & Brentjens, R. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-10940-8 · Cited by 409
IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo.
Luster, A. D., & Leder, P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.1057 · Cited by 407
IFN-γ Suppresses IL-10 Production and Synergizes with TLR2 by Regulating GSK3 and CREB/AP-1 Proteins
Hu, X., Paik, P. K., Chen, J., Yarilina, A., Kockeritz, L., Lu, T. T., Woodgett, J. R., & Ivashkiv, L. B. (2006) · Immunity · doi:10.1016/j.immuni.2006.02.014 · Cited by 406
Barth, R. J., Mulé, J. J., Spiess, P. J., & Rosenberg, S. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.647 · Cited by 402
Ito, S., Ansari, P., Sakatsume, M., Dickensheets, H., Vazquez, N., Donnelly, R. P., Larner, A. C., & Finbloom, D. S. (1999) · Blood · doi:10.1182/blood.v93.5.1456 · Cited by 389
Diverse Functions of Macrophages in Different Tumor Microenvironments
Yang, M., McKay, D., Pollard, J. W., & Lewis, C. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1367 · Cited by 387
CD4+T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
Mumberg, D., Monach, P. A., Wanderling, S., Philip, M., Toledano, A. Y., Schreiber, R. D., & Schreiber, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8633 · Cited by 384
Yoshimoto, T., Okamura, H., Tagawa, Y.-I., Iwakura, Y., & Nakanishi, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3948 · Cited by 381
Interleukin‐10 inhibits B7 and intercellular adhesion molecule‐1 expression on human monocytes
Willems, F., Marchant, A., Delville, J., Gérard, C., Delvaux, A., Velu, T., De Boer, M., & Goldman, M. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240435 · Cited by 376
Inhibitory and Stimulatory Effects of IL-10 on Human CD8+ T Cells
Groux, H., Bigler, M., de Vries, J. E., & Roncarolo, M.-G. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3188 · Cited by 376
Human Mig chemokine: biochemical and functional characterization.
Liao, F., Rabin, R. L., Yannelli, J. R., Koniaris, L. G., Vanguri, P., & Farber, J. M. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1301 · Cited by 373
Tumor-Associated Macrophages: Implications in Cancer Immunotherapy
Petty, A. J., & Yang, Y. (2017) · Immunotherapy · doi:10.2217/imt-2016-0135 · Cited by 363
Glucose Availability Regulates IFN-γ Production and p70S6 Kinase Activation in CD8+ Effector T Cells
Cham, C. M., & Gajewski, T. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4670 · Cited by 359
Emerging concepts of T cell metabolism as a target of immunotherapy
Chang, C.-H., & Pearce, E. L. (2016) · Nature Immunology · doi:10.1038/ni.3415 · Cited by 338
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Atefi, M., Avramis, E., Lassen, A., Wong, D. J. L., Robert, L., Foulad, D., Cerniglia, M., Titz, B., Chodon, T., Graeber, T. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2797 · Cited by 334
Clinical Trials: IL-12 Deaths: Explanation and a Puzzle
Cohen, J. (1995) · Science · doi:10.1126/science.270.5238.908a · Cited by 332
Interleukin 12–dependent Interferon γ Production by CD8α+Lymphoid Dendritic Cells
Ohteki, T., Fukao, T., Suzue, K., Maki, C., Ito, M., Nakamura, M., & Koyasu, S. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.12.1981 · Cited by 332
Kim, J., Modlin, R. L., Moy, R. L., Dubinett, S. M., McHugh, T., Nickoloff, B. J., & Uyemura, K. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.4.2240 · Cited by 323
Gaczynska, M., Rock, K. L., Spies, T., & Goldberg, A. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9213 · Cited by 312
Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma
Gleave, M. E., Elhilali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., Klotz, L. H., Moore, M. J., Paton, V., Bajamonde, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381804 · Cited by 308
Zhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2011) · Molecular Therapy · doi:10.1038/mt.2010.313 · Cited by 293
Interferon gamma inhibits interleukin 10 production by monocytes.
Chomarat, P., Rissoan, M. C., Banchereau, J., & Miossec, P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.2.523 · Cited by 287
Interferon‐γ activation of polymorphonuclear neutrophil function
Ellis, T. N., & Beaman, B. L. (2004) · Immunology · doi:10.1111/j.1365-2567.2004.01849.x · Cited by 285
Lack of Interferon γ Receptor β Chain and the Prevention of Interferon γ Signaling in T H 1 Cells
Pernis, A., Gupta, S., Gollob, K. J., Garfein, E., Coffman, R. L., Schindler, C., & Rothman, P. (1995) · Science · doi:10.1126/science.7618088 · Cited by 285
Xu, X., Fu, X.-Y., PLATE, J. M. D., & Chong, A. S. (1998) · PubMed · Cited by 283
Yu, J., Wei, M., Becknell, B., Trotta, R., Liu, S., Boyd, Z., Jaung, M. S., Blaser, B. W., Sun, J., Benson, D. M., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.03.016 · Cited by 279
Wolf, P. R., & Ploegh, H. L. (1995) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cb.11.110195.001411 · Cited by 278
Chinnasamy, D., Yu, Z., Kerkar, S. P., Zhang, L., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3050 · Cited by 277
Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy
Draghiciu, O., Lubbers, J., Nijman, H. W., & Daemen, T. (2015) · OncoImmunology · doi:10.4161/21624011.2014.954829 · Cited by 274
Cancer cell and macrophage cross-talk in the tumor microenvironment
Dehne, N., Mora, J., Namgaladze, D., Weigert, A., & Brüne, B. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.04.007 · Cited by 263
IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway
Fulda, S., & Debatin, K.-M. (2002) · Oncogene · doi:10.1038/sj.onc.1205255 · Cited by 260
Kerkar, S. P., Muranski, P., Kaiser, A., Boni, A., Sanchez-Perez, L., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254
Naing, A., Infante, J. R., Papadopoulos, K. P., Chan, I. H., Shen, C., Ratti, N. P., Rojo, B., Autio, K. A., Wong, D. J., Patel, M. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.007 · Cited by 251
Gastl, G. A., Abrams, J. S., Nanus, D. M., Oosterkamp, R., Silver, J., Liu, F., Chen, M., Albino, A. P., & Bander, N. H. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550118 · Cited by 242
IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells.
Wu, C. Y., Demeure, C., Kiniwa, M., Gately, M., & Delespesse, G. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.4.1938 · Cited by 222
Ligand-Induced Autoregulation of IFN-γ Receptor β Chain Expression in T Helper Cell Subsets
Bach, E. A., Szabo, S. J., Dighe, A. S., Ashkenazi, A., Aguet, M., Murphy, K. M., & Schreiber, R. D. (1995) · Science · doi:10.1126/science.270.5239.1215 · Cited by 214
Orange, J. S., Salazar-Mather, T. P., Opal, S. M., Spencer, R. L., Miller, A. H., McEwen, B. S., & Biron, C. A. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.3.901 · Cited by 207
Lee, J. H., Elly, C., Park, Y., & Liu, Y.-C. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.016 · Cited by 203
Kang, K., Park, S. H., Chen, J., Qiao, Y., Giannopoulou, E., Berg, K., Hanidu, A., Li, J., Nabozny, G., Kang, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.017 · Cited by 196 · cited 1×
“IFN-γ signaling is able to repress tumorigenic M2-differentiation of macrophages [53].”
The Roles of IL-12 in Providing a Third Signal for Clonal Expansion of Naive CD8 T Cells
Valenzuela, J., Schmidt, C., & Mescher, M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.6842 · Cited by 193
Harris, D. P., Goodrich, S., Gerth, A. J., Peng, S. L., & Lund, F. E. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6781 · Cited by 191
FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease
Kryczek, I., Liu, R., Wang, G., Wu, K., Shu, X., Szeliga, W., Vatan, L., Finlayson, E., Huang, E., Simeone, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3804 · Cited by 179
Strauss, J., Heery, C. R., Kim, J. W., Jochems, C., Donahue, R. N., Montgomery, A. S., McMahon, S., Lamping, E., Marté, J. L., Madan, R. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1512 · Cited by 171
Not All Immune Checkpoints Are Created Equal
Linhares, A. D. S., Leitner, J. M., Grabmeier‐Pfistershammer, K., & Steinberger, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01909 · Cited by 167
Human tumor-infiltrating lymphocytes: a marker of host response.
Vose, B. M., & Moore, M. G. (1985) · PubMed · Cited by 166
Interleukin 10 (IL-10)-mediated Immunosuppression
Mittal, S. K., Cho, K.-J., Ishido, S., & Roche, P. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.682708 · Cited by 166
Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis
Zhao, S., Wu, D., Wu, P., Wang, Z., & Huang, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139598 · Cited by 164
Gamma interferon is able to enhance the oxidative metabolism of human neutrophils
Berton, G., Zeni, L., Cassatella, M. A., & Rossi, F. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(86)80421-1 · Cited by 160
TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours
Conroy, H., Marshall, N. A., & Mills, K. H. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210910 · Cited by 160
Mitra, R. S., Judge, T. A., Nestle, F. O., Turka, L. A., & Nickoloff, B. J. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.6.2668 · Cited by 156
Structure of the IFNγ receptor complex guides design of biased agonists
Mendoza, J. L., Escalante, N. K., Jude, K. M., Bellón, J. S., Su, L., Horton, T. M., Tsutsumi, N., Berardinelli, S. J., Haltiwanger, R. S., Piehler, J., et al. (2019) · Nature · doi:10.1038/s41586-019-0988-7 · Cited by 150
Constitutive and Inducible Expression of B7 Family of Ligands by Human Airway Epithelial Cells
Kim, J., Myers, A. C., Chen, L., Pardoll, D. M., Truong-Tran, Q. A., Lane, A. P., McDyer, J. F., Fortuno, L. V., & Schleimer, R. P. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0129oc · Cited by 148
Kilinc, M. O., Aulakh, K. S., Nair, R. E., Jones, S. A., Alard, P., Kosiewicz, M. M., & Egilmez, N. K. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6962 · Cited by 148
Interferon-γ is an autocrine mediator for dendritic cell maturation
Pan, J., Zhang, M., Wang, J., Wang, Q., Xia, D., Sun, W., Zhang, L., Yu, H. C., Liu, Y.-J., & Cao, X. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.05.003 · Cited by 144
IL-10 secreted by M2 macrophage promoted tumorigenesis through interaction with JAK2 in glioma
Qi, L., Yu, H., Zhang, Y., Zhao, D., Lv, P., Zhong, Y., & Xu, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12317 · Cited by 137
Meng, R. D., & El‐Deiry, W. S. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5073 · Cited by 130
Park, I. A., Hwang, S.-H., Song, I. H., Heo, S., Kim, Y., Bang, W. S., Park, H. S., Lee, M., Gong, G., & Lee, H. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182786 · Cited by 127
Matsushita, H., Hosoi, A., Ueha, S., Abe, J., Fujieda, N., Tomura, M., Maekawa, R., Matsushima, K., Ohara, O., & Kakimi, K. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0098 · Cited by 121
Beatty, G. L., & Paterson, Y. Y. W. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5502 · Cited by 119
Lee, S. H., Fragoso, M. F., & Biron, C. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201528 · Cited by 114
In human B cells, IL-12 triggers a cascade of molecular events similar to Th1 commitment
Duralı, D., de Herve, M.-G. D. G., Giron‐Michel, J., Azzarone, B. G., Delfraissy, J., & Taoufik, Y. (2003) · Blood · doi:10.1182/blood-2003-02-0518 · Cited by 111
Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review)
Yu, Y., & Cui, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9219 · Cited by 108
Olalekan, S. A., Cao, Y., Hamel, K. M., & Finnegan, A. (2015) · European Journal of Immunology · doi:10.1002/eji.201445036 · Cited by 107
Akazawa, T., Masuda, H., Saeki, Y., Matsumoto, M., Takeda, K., Tsujimura, K., Kuzushima, K., Takahashi, T., Azuma, I., Akira, S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1518 · Cited by 106
Leite‐de‐Moraes, M., Moreau, G., Arnould, A., Machavoine, F., Cordier, C., Papiernik, M., & Dy, M. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199805)28:05<1507::aid-immu1507>3.0.co;2-f · Cited by 102
Interleukin 2 in Cancer Therapy
Antony, G. K., & Dudek, A. Z. (2012) · Current Medicinal Chemistry · doi:10.2174/092986710793176410 · Cited by 102
Harvat, B. L., Seth, P. K., & Jetten, A. M. (1997) · Oncogene · doi:10.1038/sj.onc.1201055 · Cited by 98
Novelli, F., Bernabei, P., Ozmen, L., Rigamonti, L., Allione, A., Pestka, S., Garotta, G., & Forni, G. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.5.1935 · Cited by 97
Mechanism of inhibition of LPS-induced IL-12p40 production by IL-10 and TGF-β in ANA-1 cells
Du, C., & Sriram, S. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.64.1.92 · Cited by 95
Heo, D. S., Whiteside, T. L., KANBOUR, A. I., & Herberman, R. B. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.11.4042 · Cited by 92
Cytokines Involved in Interferon-γ Production by Human Macrophages
Robinson, C. M., O’Dee, D. M., Hamilton, T., & Nau, G. J. (2009) · Journal of Innate Immunity · doi:10.1159/000247156 · Cited by 86
Therapy of chronic myelogenous leukemia with recombinant interferon- gamma
Kurzrock, R., Talpaz, M., Kantarjian, H., Walters, R. S., Saks, S. R., Trujillo, J., & Gutterman, J. U. (1987) · Blood · doi:10.1182/blood.v70.4.943.943 · Cited by 86
Niewerth, D., Kaspers, G. J. L., Assaraf, Y. G., van Meerloo, J., Kirk, C. J., Anderl, J. L., Blank, J. L., van de Ven, P. M., Zweegman, S., Jansen, G., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-7 · Cited by 85
Adjuvant Interferon Therapy for Melanoma: High-Dose, Low-Dose, No Dose, Which Dose?
Schuchter, L. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.907 · Cited by 85
Song, S. M., Ling-Hu, H., Roebuck, K. A., Rabbi, M. F., Donnelly, R. P., & Finnegan, A. (1997) · Blood · doi:10.1182/blood.v89.12.4461 · Cited by 85
Chan, L. L. Y., Cheung, B. K. W., Li, J., & Lau, A. S. Y. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1009659 · Cited by 83
Human monocytes produce interferon-gamma upon stimulation with LPS
Kraaij, M. D., Vereyken, E. J. F., Leenen, P. J. M., van den Bosch, T. P. P., Rezaee, F., Betjes, M. G. H., Baan, C. C., & Rowshani, A. T. (2014) · Cytokine · doi:10.1016/j.cyto.2014.02.001 · Cited by 77
McPherson, R. C., Konkel, J. E., Prendergast, C. T., Thomson, J. P., Ottaviano, R., Leech, M. D., Kay, O., Zandee, S., Sweenie, C. H., Wraith, D. C., et al. (2014) · eLife · doi:10.7554/elife.03416 · Cited by 71
Lee, J., Sayers, T. J., Brooks, A. D., Back, T. C., Young, H. A., Komschlies, K. L., Wigginton, J. M., & Wiltrout, R. H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.231 · Cited by 69
Self-citationSchiller, J. H., Pugh, M., Kirkwood, J. M., Karp, D. D., Larson, M., & Borden, E. C. (1996) · PubMed · Cited by 66
Wiesenfeld, M., O'Connell, M. J., Wieand, H. S., Gonchoroff, N. J., Donohue, J. H., Fitzgibbons, R. J., Krook, J. E., Mailliard, J. A., Gerstner, J. B., & Pazdur, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2324 · Cited by 64
Wu, C.-J., Tsai, Y.-T., Lee, I., Wu, P., Lu, L., Tsao, W.-S., Huang, Y.-J., Chang, C.-C., Ka, S., & Tao, M. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1477459 · Cited by 61
Drennan, S., Stafford, N. D., Greenman, J., & Green, V. L. (2013) · Immunology · doi:10.1111/imm.12144 · Cited by 58
Eckert, F., Jelas, I., Oehme, M., Huber, S. M., Sonntag, K., Welker, C., Gillies, S. D., Strittmatter, W., Zips, D., Handgretinger, R., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1323161 · Cited by 52
Mauldin, I. S., Wages, N. A., Stowman, A. M., Wang, E., Smolkin, M. E., Olson, W. C., Deacon, D. H., Smith, K. T., Galeassi, N., Chianese‐Bullock, K. A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1881-y · Cited by 51
Dighe, A. S., Farrar, M. A., & Schreiber, R. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82246-3 · Cited by 50
Gableh, F., Saeidi, M., Hemati, S., Hamdi, K., Soleimanjahi, H., Gorji, A., & Ghaemi, A. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0238-3 · Cited by 50
Salem, M. L., Kadima, A. N., Zhou, Y., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5159 · Cited by 46
Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8+ T cells
Rubinstein, M. P., Su, E. W., Suriano, S., Cloud, C. A., Andrijauskaite, K., Kesarwani, P., Schwartz, K. M., Williams, K. M., Johnson, C. B., Li, M., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1655-y · Cited by 45
IL-12 Gene Electrotransfer Triggers a Change in Immune Response within Mouse Tumors
Shi, G., Edelblute, C. M., Arpag, S., Lundberg, C. G., & Heller, R. F. (2018) · Cancers · doi:10.3390/cancers10120498 · Cited by 45
Methylation Patterns of the IFN-γ Gene in Cervical Cancer Tissues
Ma, D., Jiang, C., Hu, X., Liu, H., Li, Q., Li, T., Yang, Y., & Li, O. (2014) · Scientific Reports · doi:10.1038/srep06331 · Cited by 43
Rubinstein, M. P., Cloud, C. A., Garrett, T. E., Moore, C. J., Schwartz, K. M., Johnson, B. C., Craig, D., Salem, M. L., Paulos, C. M., & Cole, D. J. (2012) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2011.12.034 · Cited by 39
Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells
Alsaieedi, A., Holler, A., Veliça, P., Bendle, G. M., & Stauss, H. J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1542917 · Cited by 38
IL-12 Signals through the TCR To Support CD8 Innate Immune Responses
Goplen, N., Saxena, V., Knudson, K. M., Schrum, A. G., Gil, D., Daniëls, M. A., Zamoyska, R., & Teixeiro, E. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600037 · Cited by 37
IL-12 Enhances CTL Synapse Formation and Induces Self-Reactivity
Markiewicz, M. A., Wise, E. L., Buchwald, Z. S., Cheney, E. E., Hansen, T. H., Suri, A., Čemerski, S., Allen, P. M., & Shaw, A. S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1351 · Cited by 35
Llovera, M., Pearson, J. D., Moreno, C., & Riveros‐Moreno, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703838 · Cited by 35
Kallal, L. E., & Biron, C. A. (2013) · JAK-STAT · doi:10.4161/jkst.23504 · Cited by 35
Management of toxicities associated with high-dose interleukin-2 and biochemotherapy
Poust, J., Woolery, J. E., & Green, M. R. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835a5ca3 · Cited by 34
Goedegebuure, P. S., Zuber, M., Leonard-Vidal, D. L., Burger, U. L., Cusack, J. C., Chang, M., Douville, L. M., & Eberlein, T. J. (1994) · Surgical Oncology · doi:10.1016/0960-7404(94)90003-5 · Cited by 33
Pyo, K., Lee, Y. W., Lim, S. M., & Shin, E. (2016) · Oncotarget · doi:10.18632/oncotarget.12316 · Cited by 33
Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation
Eckert, F., Gaipl, U. S., Niedermann, G., Hettich, M., Schilbach, K., Huber, S. M., & Zips, D. (2017) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2016.12.006 · Cited by 33
Luheshi, N., Davies, G., Poon, E., Wiggins, K. A., McCourt, M., & Legg, J. W. (2013) · European Journal of Immunology · doi:10.1002/eji.201343351 · Cited by 31
IFN-γ Negatively Regulates CpG-Induced IL-10 in Bone Marrow-Derived Dendritic Cells
Flores, R. R., Diggs, K. A., Tait, L. M., & Morel, P. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.211 · Cited by 27
Wang, L., Liu, J.-Q., Talebian, F., Liu, Z., Li, Y., & Bai, X. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1014232 · Cited by 26
Lin, L., Rayman, P. A., Pavicic, P. G., Tannenbaum, C. S., Hamilton, T. A., Montero, A. J., Ko, J. S., Gastman, B., Finke, J. H., Ernstoff, M. S., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2280-3 · Cited by 24
Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10
Llópiz, D., Ruiz, M., Silva, L., & Sarobe, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01923 · Cited by 21
Park, W.-R., Park, C.-S., Tomura, M., Ahn, H.-J., Nakahira, Y., 岩崎, 正., Gao, P. H., Abe, R., Hamaoka, T., & Fujiwara, H. (2001) · European Journal of Immunology · Cited by 19
Nitric oxide short-circuits interleukin-12-mediated tumor regression
Egilmez, N. K., Harden, J. L., Virtuoso, L. P., Schwendener, R. A., & Kilinc, M. O. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-0998-2 · Cited by 18
Prat, M., Bretti, S., Amedeo, M. R., Landolfo, S., & Comoglio, P. M. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.12.4530 · Cited by 17
Vahdat, L. T., Cohen, D. J., Zipin, D., Lo, K. S., Donovan, D., Savage, D. G., Tiersten, A., NICHOLS, G. L., Troxel, A. B., & Hesdorffer, C. S. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705692 · Cited by 14
Hoff, D. D. V., Fleming, T. R., Macdonald, J. S., Goodman, P. J., Damme, J. V., Brown, T. D., O’Rourke, T. J., Feun, L. G., & Keppen, M. D. (1990) · PubMed · Cited by 12
Tsuchihashi (2000) · doi:10.1002/1521-4141(200006)30:6
Research works printed but not linked: 9
- Langer, 1994, Radiation inactivation of human gamma-interferon: cellular activation requires two dimers, Proc. Natl. Acad. Sci. U. S. A., 91, 5818, 10.1073/pnas.91.13.5818 · doi:10.1073/pnas.91.13.5818
- Yamashita, 1997, Nitric oxide is an effector molecule in inhibition of tumor cell growth by rIFN-gamma-activated rat neutrophils, Int. J. Cancer, 71, 223, 10.1002/(SICI)1097-0215(19970410)71:2<223::AID-IJC17>3.0.CO;2-I · doi:10.1002/(sici)1097-0215(19970410)71:2<223::aid-ijc17>3.0.co;2-i
- Hesse, 1984, Decreased T lymphocyte migration in patients with malignancy mediated by a suppressor cell population, J. Clin. Invest., 73, 1078, 10.1172/JCI111293 · doi:10.1172/jci111293
- Whittaker, 1971, Depressed lymphocyte function in carcinoma of the breast, Br. J. Surg., 58, 717, 10.1002/bjs.1800581002 · doi:10.1002/bjs.1800581002
- McCluskey, 1983, T lymphocyte subsets in the peripheral blood of patients with benign and malignant breast disease, Br. J. Cancer, 47, 307, 10.1038/bjc.1983.41 · doi:10.1038/bjc.1983.41
- Kawamura, 1995, Comparative analysis of B7-1 and B7-2 expression in Langerhans cells: differential regulation by T helper type 1 and T helper type 2 cytokines, Eur. J. Immunol., 25, 1913, 10.1002/eji.1830250718 · DOI
- Joss, 2000, IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway, Eur. J. Immunol., 30, 1683, 10.1002/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A · doi:10.1002/1521-4141(200006)30:6<1683::aid-immu1683>3.0.co;2-a
- Cohen, 1995, IL-12 deaths: explanation and a puzzle, Science, 270, 908, 10.1126/science.270.5238.908.a · doi:10.1126/science.270.5238.908.a · Paper page
- Cha, 2012, Plasmid IL-12 electroporation in melanoma, Hum. Vaccin. Immunother., 8, 1734, 10.4161/hv.22573 · doi:10.4161/hv.22573
Cited by
Roles of IFN-γ in tumor progression and regression: A review
Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00228-x · Cited by 1,234
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
Bald, T., Krummel, M. F., Smyth, M. J., & Barry, K. C. (2020) · Nature Immunology · doi:10.1038/s41590-020-0728-z · Cited by 506
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Sepsis-Induced Immunosuppression
Torres, L. K., Pickkers, P., & van der Poll, T. (2022) · Annual Review of Physiology · doi:10.1146/annurev-physiol-061121-040214 · Cited by 355
Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy
Correia, A. L., Guimaraes, J. C., Auf der Maur, P., De Silva, D., Trefny, M. P., Okamoto, R., Bruno, S., Schmidt, A., Mertz, K., Volkmann, K., et al. (2021) · Nature · doi:10.1038/s41586-021-03614-z · Cited by 339
Metadata
- Authors
- Burke, J. D., & Young, H. A.
- Venue
- Seminars in Immunology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 43
- Pages
- 101280
- ISSN
- 1044-5323 (ISSN-L)
- OpenAlex
- W2951756816
- Cited by
- 254
- References
- 194
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.